ABVC BioPharma, Inc. (ABVC) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -894.24K | -1.42M | -133.26K | -894.17K | -539.83K | -493.61K | 171.72K | -211.43K | -955.82K | -430.46K | -1.36M | -899.83K |
| Operating CF Margin % | - | 178.28% | - | - | - | -25107.38% | 44.11% | -180.49% | -79320.83% | -19882.82% | -8555.31% | -14729.53% |
| Operating CF Growth % | -65.65% | -187.48% | -177.6% | -322.93% | 43.52% | -14.67% | 112.64% | 76.5% | 36.18% | 6.64% | -164.53% | 73.76% |
| Net Income | -1.69M | -3.81M | -1.25M | -2.26M | -944.19K | 229.3K | -186.56K | -942.34K | -2.83M | -383.33K | -3.37M | -2.26M |
| Depreciation & Amortization | 92.16K | 214.04K | 96.01K | 80.83K | 113.95K | 179.32K | 7.01K | 114.33K | 102.55K | 359.44K | 7.46K | 7K |
| Stock-Based Compensation | 787.37K | 1.39M | 1.14M | 1.57M | 48.77K | -184.28K | 0 | 282.88K | 2.03M | -1.22M | 817.74K | 225.74K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -117.41K | 0 |
| Other Non-Cash Items | 32.58K | 865.04K | 21.84K | 99.87K | 260.92K | -495.78K | 338.66K | 46.33K | 82.81K | 1.41M | 1.3M | 261.3K |
| Working Capital Changes | -116.42K | -71.92K | -140.81K | -389.46K | -19.28K | -222.17K | 12.61K | 287.38K | -338.61K | -590.26K | 1.79K | 869.64K |
| Change in Receivables | -208.89K | 33.3K | 0 | 0 | 54.11K | 0 | 0 | 0 | 0 | 37.29K | 9.7K | 68.23K |
| Change in Inventory | 0 | 0 | 0 | 0 | -11.46K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | 47.12K | 730.35K | -1.27M | -665.78K | 0 | 0 | 0 | -501.61K | 0 | 154.17K | -73.78K | -440.57K |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -21.2K | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - | 133.47% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 47.12K | 730.35K | -1.27M | -665.78K | 0 | 0 | 0 | -501.61K | 0 | 154.17K | 0 | -440.57K |
| Cash from Financing | -342.18K | 1.15M | 1.13M | 1.93M | 428.76K | 581.46K | -145.39K | 802.16K | 924.15K | 38.42K | 1.66M | -31.59K |
| Debt Issued (Net) | -661.65K | 549.88K | 150K | 0 | -29.25K | 0 | 0 | 0 | 282.1K | 110.11K | -1.82M | -31.59K |
| Equity Issued (Net) | 421.49K | 528.18K | 0 | 0 | 411.67K | -7.32K | 0 | 0 | 0 | 0 | 1.05M | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | -7.32K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -102.02K | 71.45K | 982.39K | 1.93M | 46.34K | 588.78K | -145.39K | 802.16K | 642.05K | -71.69K | 2.43M | 0 |
| Net Change in Cash | -1.19M | 473.07K | -222.41K | 316.76K | -104.25K | 93.94K | 27.1K | 83.77K | -57.78K | -404.16K | 378.75K | -1.05M |
| Free Cash Flow | -894.24K | -1.42M | -133.26K | -894.17K | -539.83K | -493.61K | 171.72K | -211.43K | -955.82K | -430.46K | -1.38M | -899.83K |
| FCF Margin % | - | 178.28% | - | - | - | -25107.38% | 44.11% | -180.49% | -79320.83% | -19882.82% | -8688.78% | -14729.53% |
| FCF Growth % | -65.65% | -187.48% | -177.6% | -322.93% | 43.52% | -14.67% | 112.44% | 76.5% | 36.18% | 6.66% | -166.4% | 73.93% |
| FCF per Share | -0.04 | -0.06 | -0.01 | -0.05 | -0.04 | -0.04 | 0.01 | -0.02 | -0.10 | -0.06 | -0.34 | -0.27 |
| FCF Conversion (FCF/Net Income) | 0.57x | 0.40x | 0.07x | 0.40x | 0.64x | -2.15x | -0.92x | 0.22x | 0.34x | 0.14x | 0.41x | 0.40x |
| Interest Paid | 0 | 9.44K | 11.57K | 5.27K | 5.23K | -39.91K | 45.96K | 10.78K | 5.7K | 5.66K | 0 | -35.13K |
| Taxes Paid | 0 | 10.06K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |